Differential Scanning Fluorimetry (DSF) & nanoDSF Lab

Conventional Differential Scanning Fluorimetry (DSF) relies on extrinsic fluorophores such as SYPRO Orange that are quenched in aqueous solution but exhibit massive fluorescence increases upon binding to hydrophobic protein cores exposed during thermal unfolding. In contrast, label-free nanoDSF measures the intrinsic fluorescence emission shift of native tryptophan and tyrosine residues at 330 nm and 350 nm. As hydrophobic core tryptophans are exposed to the polar solvent during denaturation, their emission undergoes a red shift. NanoDSF requires zero extrinsic dyes, operates in detergent micelles and lipid nanodiscs, and is immune to dye-compound optical interference.

The thermal melting temperature (Tm) corresponds to the inflection point of the sigmoidal unfolding curve where 50% of the protein population is in the native state and 50% is unfolded (fraction unfolded fu = 0.5, delta G = 0). Experimentally, Tm is determined by taking the first derivative of fluorescence or fluorescence ratio with respect to temperature (-dF/dT or d(F350/F330)/dT); the local maximum of this first derivative peak corresponds precisely to the transition midpoint.

According to Le Chatelier's principle and thermodynamic linkage theory, a ligand that binds selectively to the native folded state pulls the unfolding equilibrium towards the folded conformation, requiring additional thermal energy to unfold the complex. This increases the melting temperature (delta Tm = Tm,bound - Tm,apo > 0). Using the Gibbs-Helmholtz relation and the enthalpy of unfolding delta Hm, the dissociation constant Kd at the melting temperature can be thermodynamically estimated from the free ligand concentration and the magnitude of the thermal shift.

Fragment-based drug discovery screens chemical fragments with very low molecular weight (150-300 Da) that typically bind with weak affinity (micromolar to millimolar Kd). Conventional functional assays frequently fail to detect these weak interactions. DSF and nanoDSF provide high-throughput, miniaturized 384-well plate or capillary chip formats consuming less than 1-5 micrograms of protein per condition, providing unambiguous physical target engagement confirmation and ranking fragment stabilization prior to X-ray crystallography or Cryo-EM soaking.

A commercial nanoDSF or high-throughput DSF screening suite requires an initial instrumentation CapEx between $120,000 and $220,000. Operating costs are driven by high-precision optical capillary chips (approx. $3.50 to $6.00 per well), calibration standards, thermal ramp nitrogen purging, and bioanalytical scientist labor. High-throughput screening campaigns generating 25,000 to 50,000 data wells annually at commercial fee rates of $18 to $35 per condition achieve gross margins exceeding 75%, positive operating cash flows within 12 months, and facility net present values (NPV) exceeding $1.5M.